However, promotion of migration may be pro-tumorigenic, so further studies to determine the mechanisms underlying the differential effects of IGFBP-6 on migration in these cell lines would help in developing an IGFBP-6-based therapeutic for IGF-II-dependent cancers. This evidence concerns the gene IGF2 and cancer.